Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience

Abstract

Prior studies have reported pulmonary function tests (PFT) before and after related and unrelated allogeneic hematopoietic stem cell transplantation (HSCT). However, limited data exist on the evaluation of lung function after haploidentical stem cell transplantation (HAPLO) with post-transplant cyclophosphamide (PTCY). We retrospectively reported the evaluation of PFTs at screening before HAPLO in 80 patients at 100 days and 1 year of follow-up. The proportion of surviving patients with available PFTs at 100 days and 1 year were 86% and 68%, respectively. During the follow-up period, four patients met the criteria for bronchiolitis obliterans syndrome and two for interstitial lung disease. Overall survival was 73% (95% CI 62–82%) at 2 years. We observed a significant reduction in diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for the most recent hemoglobin concentration (DLCOc) at 100 days after HAPLO. However, an overall substantial stable pulmonary function was observed at 1 year.

Keywords:

• PFT
• HAPLO
• pulmonary function
• pulmonary function tests
• HSCT
• lung function score

Acknowledgments

The authors thank Marie Talouarn and all the transplant coordinator nurses for their help in retrieving data for this study.

Disclosure statement

Rémy Duléry reports honoraria from Keocyt, whose drug was used in the study. The other authors have no conflict of interest to disclose. Mohamad Mohty reports honoraria from Janssen, Sanofi, Maat Pharma, JAZZ pharmaceutical, Celgene, Amgen, BMS, Takeda, Pfizer, and Roche. Florent Malard reports honoraria from Therakos/Mallinckrodt, Biocodex, Janssen, Keocyt, Sanofi, JAZZ pharmaceutical and Astellas.